126 related articles for article (PubMed ID: 38530658)
1. Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes.
Mazeda C; Oliveira N; Abreu C; Fraga V; Maduro I; Saraiva A; Inês L; Ferreira C; Correia AM; Nicolau R; Farinha F; Villanueva I; Jesus D; Abreu P; Neto A; Silva Dinis J; Barcelos A
Clin Exp Rheumatol; 2024 Mar; ():. PubMed ID: 38530658
[TBL] [Abstract][Full Text] [Related]
2. Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases.
Murng SHK; Thomas M
J Clin Pathol; 2018 Jan; 71(1):12-19. PubMed ID: 28663326
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.
Robbins A; Hentzien M; Toquet S; Didier K; Servettaz A; Pham BN; Giusti D
Front Immunol; 2019; 10():444. PubMed ID: 30915082
[TBL] [Abstract][Full Text] [Related]
4. Anti-ENA profiles related with anti-SS-A/Ro. The detection of Ro52 and Ro60 according to the presence of SS-B/La, and ANA pattern and titer.
González DA; Rodríguez CC; Armas LM; Varela AR; Rodríguez IM; Duarte MT; de León AC
Immunol Lett; 2014 Sep; 161(1):6-12. PubMed ID: 24768604
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases.
Yang HT; Hong XP; Guo JW; Zhong XL; Liao R; Liu CL; Liu LX; Li K; Chen YL; Liu DZ
J Immunol Res; 2023; 2023():9195157. PubMed ID: 36741231
[TBL] [Abstract][Full Text] [Related]
6. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain.
Menor Almagro R; Jurado Roger A; Rodríguez Gutiérrez FJ; Solís Díaz R; Cardiel MH; Salaberri Maestrojuan JJ
Reumatol Clin; 2016; 12(5):256-62. PubMed ID: 26725021
[TBL] [Abstract][Full Text] [Related]
7. Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome.
Yamaguchi K; Tang Q; Poland P; Reay DP; Gregory A; Aggarwal R; Oddis CV; Ascherman DP
Front Immunol; 2024; 15():1399451. PubMed ID: 38895121
[TBL] [Abstract][Full Text] [Related]
8. Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation.
Bettacchioli E; Saraux A; Tison A; Cornec D; Dueymes M; Foulquier N; Hillion S; Roguedas-Contios AM; Benyoussef AA; Alarcon-Riquelme ME; Pers JO; Devauchelle-Pensec V;
Arthritis Rheumatol; 2024 May; 76(5):751-762. PubMed ID: 38130019
[TBL] [Abstract][Full Text] [Related]
9. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease.
Gunnarsson R; El-Hage F; Aaløkken TM; Reiseter S; Lund MB; Garen T; ; Molberg Ø
Rheumatology (Oxford); 2016 Jan; 55(1):103-8. PubMed ID: 26320136
[TBL] [Abstract][Full Text] [Related]
10. Anti-Ro52 antibodies in clinical practice: A single-centre experience.
Wu S; Tang X; Wu L; Lu L; Feng X
Int J Clin Pract; 2021 Mar; 75(3):e13679. PubMed ID: 32798318
[TBL] [Abstract][Full Text] [Related]
11. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection.
Menéndez A; Gómez J; Escanlar E; Caminal-Montero L; Mozo L
Autoimmunity; 2013 Feb; 46(1):32-9. PubMed ID: 23039326
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the clinical significance of Ro52/TRIM21 antibody and specific antinuclear antibody patterns by indirect immunofluorescence.
Liu K; Liao Y; Li P; Shi J
J Pak Med Assoc; 2024 Feb; 74(2):236-242. PubMed ID: 38419219
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases.
Decker P; Moulinet T; Lopez B; Dubucquoi S; Bonnotte B; Lakomy D; Revuz S; Luc A; Bittencourt MC; Hachulla E; Jaussaud R
Eur J Intern Med; 2021 Sep; 91():45-52. PubMed ID: 33972152
[TBL] [Abstract][Full Text] [Related]
14. Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers.
Kaizer AM; Lindblade C; Clancy R; Tebo AE; Drewes B; Masson M; Chang M; Fraser N; Buyon JP; Cuneo BF
Am J Obstet Gynecol; 2022 Nov; 227(5):761.e1-761.e10. PubMed ID: 35690080
[TBL] [Abstract][Full Text] [Related]
15. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease.
Peene I; Meheus L; De Keyser S; Humbel R; Veys EM; De Keyser F
Ann Rheum Dis; 2002 Oct; 61(10):929-33. PubMed ID: 12228166
[TBL] [Abstract][Full Text] [Related]
16. The value of separate detection of anti-Ro52, anti-Ro60 and anti-SSB/La reactivities in relation to diagnosis and phenotypes in primary Sjögren's syndrome.
Deroo L; Achten H; De Boeck K; Genbrugge E; Bauters W; Roels D; Dochy F; Creytens D; Deprez J; Van den Bosch F; Elewaut D; Peene I
Clin Exp Rheumatol; 2022 Dec; 40(12):2310-1317. PubMed ID: 36200940
[TBL] [Abstract][Full Text] [Related]
17. Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus.
Menéndez A; Gómez J; Caminal-Montero L; Díaz-López JB; Cabezas-Rodríguez I; Mozo L
ScientificWorldJournal; 2013; 2013():832789. PubMed ID: 24294139
[TBL] [Abstract][Full Text] [Related]
18. Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations.
Zampeli E; Mavrommati M; Moutsopoulos HM; Skopouli FN
Clin Exp Rheumatol; 2020; 38 Suppl 126(4):134-141. PubMed ID: 32083547
[TBL] [Abstract][Full Text] [Related]
19. Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren's syndrome in the absence of anti-SSA/SSB antibodies by ELISA.
Mekinian A; Nicaise-Roland P; Chollet-Martin S; Fain O; Crestani B
Rheumatology (Oxford); 2013 Dec; 52(12):2223-8. PubMed ID: 24026249
[TBL] [Abstract][Full Text] [Related]
20. Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study.
Vázquez-Del Mercado M; Martínez-García EA; Daneri-Navarro A; Gómez-Bañuelos E; Martín-Márquez BT; Pizano-Martínez O; Wilson-Manríquez EA; Corona-Sánchez EG; Chavarria-Avila E; Sandoval-García F; Satoh M
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):328-333. PubMed ID: 33876712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
